• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 13, 2022 at 11:52: PM
via Relmada Therapeutics' RELIANCE III trial studying REL-1017 as a treatment for Major Depressive Disorder failed to hit the primary endpoint, the company announced Thursday. At some study sites, there were “paradoxical results," Relmada reported.

article source
 




Top Bottom
Back
Quote